Monsanto Pension Plan

Monsanto Pension Plan

The Monsanto Pension Plan descends from the UK pension arrangements of Monsanto Company, the US agribusiness acquired by Bayer in 2018. Following corporate restructuring, Pharmacia Limited — a Pfizer Group subsidiary — became the sponsoring employer, making this a Swiss-headquartered scheme with UK liabilities and ties to two global pharmaceutical parents. The plan's Trustees operate at arm's length from the sponsor. Investment strategy spans venture capital, growth equity, buyout, mezzanine, secondaries, and special situations, executed via a fund-of-funds and co-investment approach. The plan's most visible transaction was a c£100m pensioner buy-in with Scottish Widows in 2017, shifting longevity and investment risk off the balance sheet for a defined cohort of retirees. Private markets allocations appear to cover early-stage (seed and start-up) through late-stage expansion, with additional exposure to turnaround and distressed situations. Trustee governance sits with a board chaired by Michael Chatterton as of 2024, succeeding former chair Nita Tinn. No dedicated investment team or professional headcount is publicly documented, suggesting the plan relies on external investment consultants and fiduciary managers for portfolio construction and manager selection. The Pfizer connection provides a pharmaceutical-sector legacy but no disclosed co-investment relationship. Structurally, the Monsanto Pension Plan is an orphaned corporate scheme — a UK pension vehicle whose original namesake company no longer exists in independent form, and whose sponsor sits inside a larger pharmaceutical conglomerate. This architecture creates a pure liability-driven governance posture, where de-risking and run-off management likely dominate current priorities over new risk-taking.